Companies › Arthrosi Therapeutics
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 3; Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| XOI High Dose Xanthine oxidase inhibitor | XDH | Phase 3 | Gout | Nov 2026 |
| XOI Low Dose Xanthine oxidase inhibitor | XDH | Phase 2 | Gout | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06846515 | XOI High Dose | Phase 3 | Gout | Immunology | Aug 2026 |
| NCT07116746 | XOI Low Dose | Phase 2 | Gout | Immunology | Nov 2026 |
| NCT07116746 | XOI High Dose | Phase 2 | Gout | Immunology | Nov 2026 |
Shenyang Sunshine Pharmaceutical Shanghai Institute Of Biological Products Innovent Biologics Technology Limited (Shanghai R&D Center)
Paradigm Biopharmaceuticals Triveni Bio Hangzhou Highlightll Pharmaceutical Integrative Skin Science and Research MRM Health
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.